Dermatitis, Atopic Clinical Trial
Official title:
An Open-label, Controlled Phase I Pilot Study to Evaluate Safety and Immunogenicity of MVA-BN® Smallpox Vaccine in 18-40 Year Old Vaccinia-naïve Subjects With Atopic Disorders
NCT number | NCT00189917 |
Other study ID # | POX-MVA-007 |
Secondary ID | N01-AI-30016 |
Status | Completed |
Phase | Phase 1 |
First received | |
Last updated | |
Start date | April 2004 |
Verified date | January 2019 |
Source | Bavarian Nordic |
Contact | n/a |
Is FDA regulated | No |
Health authority | |
Study type | Interventional |
The purpose of this study is to gather information on the safety and immunogenicity of an investigational smallpox vaccine in populations with atopic disorders.
Status | Completed |
Enrollment | 60 |
Est. completion date | |
Est. primary completion date | December 2005 |
Accepts healthy volunteers | Accepts Healthy Volunteers |
Gender | All |
Age group | 18 Years to 40 Years |
Eligibility |
Inclusion Criteria: All subjects - Age 18-40. - Read, signed and dated informed consent. - Women of childbearing potential must use an acceptable method of contraception Group 1: Healthy subjects - No history of atopic dermatitis as documented in the patient file - No active atopic dermatitis - No other atopic disorders such as asthma or allergic rhinitis. - Prick test without clinical significance - IgE within normal range Group 2: Subjects with history of atopic dermatitis Group 3: Subjects with mild active atopic dermatitis - SCORAD 1 - 15. Group 4: Subjects with mild allergic rhinitis - At least one active allergic rhinitis phase during last year. Exclusion Criteria: - Known or suspected history of smallpox vaccination or typical vaccinia scar. - Positive test result in MVA specific ELISA at screening. - Positive result in HIV or HCV antibody test at screening. - Surface antigen of Hepatitis B Virus (HBsAg) positive at screening. - Pregnant or breast-feeding women. - Positive pregnancy test at screening and/or within 24 hours prior to vaccination. - Alanine aminotransferase (ALT) or aspartate aminotransferase (AST) above the institutional upper limit of normal. - Positive urine glucose by dipstick or urine analysis. - Inadequate renal function defined as a serum creatinine above the institutional upper limit of normal; urine protein >30 mg/dl or trace proteinuria (by urine analysis or dipstick); and a calculated creatinine clearance <80 ml/min. - Electrocardiogram (ECG) with clinical significance. - Hemoglobin <11 g/dl; White blood cells less than 2,500 and more than 11,000/mm3; Platelets less than 140,000/mm3. - Uncontrolled serious infection i.e. not responding to antimicrobial therapy. - History of any serious medical condition, which in the opinion of the investigator would compromise the safety of the subject. - History of or active autoimmune disease. - Known or suspected impairment of immunologic function including, but not limited to, clinically significant liver disease; diabetes mellitus; moderate to severe kidney impairment. - History of malignancy. - History or clinical manifestation of clinically significant mental illness or haematological, renal, hepatic, pulmonary, central nervous, cardiovascular or gastrointestinal disorders. - Any condition which might interfere with study objectives. - History of immunodeficiency. - History of myocardial infarction, angina, congestive heart failure, cardiomyopathy, stroke or transient ischemic attack, or other heart condition under the care of a doctor. - Three or more of the following risk factors: High blood pressure, high blood cholesterol, diabetes mellitus or high blood sugar, a first degree relative who had a heart condition before the age of 50, smoking cigarettes. - History of chronic alcohol abuse and/or intravenous drug abuse. - History of allergic reactions likely to be exacerbated by any component of the vaccine. - History of anaphylaxis or severe allergic reaction. - Acute disease (illness with or without a fever) at the time of enrollment. - Any vaccinations within a period starting 30 days prior to administration of the vaccine and ending at study conclusion. - Chronic administration of immuno-suppressant or immune-modifying drugs. - Post organ transplant subjects whether or not receiving chronic immunosuppressive therapy. - Administration or planned administration of immunoglobulins and/or any blood -- Use of any investigational or non-registered drug. - Blood donation 8 weeks in advance or during study participation. |
Country | Name | City | State |
---|---|---|---|
Germany | Department of Infectious Diseases and Tropical Medicine | Munich | Bavaria |
Lead Sponsor | Collaborator |
---|---|
Bavarian Nordic | National Institute of Allergy and Infectious Diseases (NIAID) |
Germany,
Darsow U, Sbornik M, Rombold S, Katzer K, von Sonnenburg F, Behrendt H, Ring J. Long-term safety of replication-defective smallpox vaccine (MVA-BN) in atopic eczema and allergic rhinitis. J Eur Acad Dermatol Venereol. 2016 Nov;30(11):1971-1977. doi: 10.11 — View Citation
von Sonnenburg F, Perona P, Darsow U, Ring J, von Krempelhuber A, Vollmar J, Roesch S, Baedeker N, Kollaritsch H, Chaplin P. Safety and immunogenicity of modified vaccinia Ankara as a smallpox vaccine in people with atopic dermatitis. Vaccine. 2014 Sep 29 — View Citation
Type | Measure | Description | Time frame | Safety issue |
---|---|---|---|---|
Primary | Occurrence, relationship and intensity of any serious adverse event at any time during the study. | |||
Secondary | ELISA specific seroconversion rates and geometric mean titres (at all blood sampling time points). | |||
Secondary | Neutralisation assay specific seroconversion rates and geometric mean titres (at all blood sampling time points). |
Status | Clinical Trial | Phase | |
---|---|---|---|
Completed |
NCT03563066 -
Effect of Benralizumab in Atopic Dermatitis
|
Phase 2 | |
Terminated |
NCT04086121 -
A Study to Test the Long-term Safety of BI 655130 in Patients With Atopic Eczema Who Took Part in Study 1368-0032
|
Phase 2 | |
Recruiting |
NCT04011215 -
Wool Clothing for the Management of Childhood Atopic Dermatitis (DESSINE2)
|
N/A | |
Completed |
NCT04635072 -
Stabilized Whole Rice Bran (SWRB) for Mild to Moderate Atopic Dermatitis
|
Early Phase 1 | |
Completed |
NCT02916888 -
A Study Comparing the Quality of Life of Patients in the Treatment of Eczema by Pediatric Generalists and Specialists
|
N/A | |
Completed |
NCT01945086 -
A Study of Ustekinumab (STELARA®) in Adult Japanese Participants With Severe Atopic Dermatitis
|
Phase 2 | |
Completed |
NCT00541255 -
A Long-Term Examination of Asthma From Childhood Through Adolescence
|
||
Terminated |
NCT04990440 -
A Study of Bermekimab for the Treatment of Adult Participants With Moderate-to-Severe Atopic Dermatitis
|
Phase 2 | |
Completed |
NCT02900131 -
Efficacy, Safety and Dose Finding Trial of Topical Jaungo Application in Atopic Dermatitis Patients
|
Phase 2 | |
Completed |
NCT03568136 -
Investigation of Efficacy of Secukinumab in Patients With Moderate to Serve Atopic Dermatitis
|
Phase 2 | |
Recruiting |
NCT01631617 -
Effects of Treatments on Atopic Dermatitis
|
Phase 2 | |
Completed |
NCT03672383 -
Functional Study to Investigate the Efficacy of a New Medical Device (Modified Diprobase Formulation)
|
N/A | |
Completed |
NCT03634345 -
Drug Drug Interaction Study Evaluating the Effect of Fluvoxamine or Fluconazole on PK and Safety of PF-04965842.
|
Phase 1 | |
Enrolling by invitation |
NCT04761978 -
Efficacy and Tolerance of JAK Inhibitors in ATU for Atopic Dermatitis
|
||
Completed |
NCT03663673 -
Effect of Different Skin Creams on TEWL
|
Phase 1 | |
Recruiting |
NCT05177744 -
Toxicity of Micro and Nano Plastics Combined With Environmental Contaminants on the Risk of Allergic Disease
|
||
Completed |
NCT03720470 -
Study Evaluating Efficacy and Safety of PF-04965842 and Dupilumab in Adult Subjects With Moderate to Severe Atopic Dermatitis on Background Topical Therapy
|
Phase 3 | |
Completed |
NCT02637206 -
Skin Irritation Study of GSK2894512 Cream
|
Phase 1 | |
Completed |
NCT05544591 -
Evaluation of 611 in Chinese Adults With Moderate to Severe Atopic Dermatitis
|
Phase 2 | |
Completed |
NCT05094700 -
A Study of a Polymeric Surfactant Technology Cleanser in Sensitive Skin Participants
|
N/A |